A Payor Goes Head-to-Head With NIH's Genetic-Testing Registry, While a Pharma Focuses on Patients

Blue Cross Blue Shield "supports a mandatory registry" and is in favor of giving the NIH greater regulatory powers to enforce it, while Boehringer Ingelheim stresses how the registry will impact patients.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.